Human papillomavirus type 16 E7 messenger RNA (HPV16 E7 mRNA) (HPV16 E7 mRNA)

Human papillomavirus type 16 (HPV16) E7 messenger RNA (mRNA) is a critical viral transcript involved in the development and maintenance of HPV-associated malignancies, including cervical, oropharyngeal, and anogenital cancers (National Cancer Institute, 2023). The mRNA encodes the E7 oncoprotein, which plays a pivotal role in oncogenesis by binding to and inducing the degradation of the Retinoblastoma protein (pRb), a key tumor suppressor (UniProtKB - P03129). This interaction disrupts cell cycle control, leading to the constitutive activation of E2F transcription factors and subsequent uncontrolled cellular proliferation (StatPearls, 2023). Because the expression of E7 is required for the survival of HPV-transformed cells, the E7 mRNA serves as an ideal therapeutic target for highly specific interventions (PubMed: 31554601). Current therapeutic strategies include the use of small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) to silence the transcript, as well as mRNA-based vaccines like BNT113 that utilize the E7 sequence to prime the immune system against infected cells (BioNTech, 2024). Targeting this viral component offers a high degree of selectivity, as the sequence is absent in healthy human cells, potentially minimizing off-target toxicity.

Other names

HPV-16 E7 mRNAHPV16 E7 transcriptHuman papillomavirus 16 E7 mRNA

The mechanism of action involves the targeted degradation of the viral transcript via RNA interference (siRNA) or antisense oligonucleotides (ASO) to prevent oncoprotein synthesis, or the use of the mRNA sequence in vaccines to elicit a cytotoxic T-lymphocyte response against E7-expressing cells (PubMed: 31554601, BioNTech, 2024).